• 1. An amorphous Cu–In–S nanoparticle-based precursor ink with improved atom economy for CuInSe2 solar cells with 10.85% efficiency?
  Green Chem., 2017,19, 1268-1277
• 2. Alt-proteins: A promising future
• 3. Acenaphthenic hopanoids, a novel series of aromatised
  Teresita Carrillo-Hernández,Philippe Schaeffer,Pierre Albrecht Chem. Commun., 2001, 1976-1977
• 4. Acetyl group orientation modulates the electronic ground-state asymmetry of the special pair in purple bacterial reaction centers
  P. K. Wawrzyniak,M. T. P. Beerepoot,H. J. M. de Groot,F. Buda Phys. Chem. Chem. Phys., 2011,13, 10270-10279
• 5. An arsenic trioxide nanoparticle prodrug (ATONP) potentiates a therapeutic effect on an aggressive hepatocellular carcinoma model via enhancement of intratumoral arsenic accumulation and disturbance of the tumor microenvironment?
  Xin Fu,Qing-rong Liang,Rong-guang Luo,Yan-shu Li,Xiao-ping Xiao,Lu-lu Yu,Wen-zhe Shan,Guang-qin Fan J. Mater. Chem. B, 2019,7, 3088-3099

Recent Advances in the Application of 2-Ethynyl-4-(trifluoromethyl)pyridine (CAS: 512197-90-9) in Chemical Biology and Pharmaceutical Research

The compound 2-ethynyl-4-(trifluoromethyl)pyridine (CAS: 512197-90-9) has recently emerged as a key building block in chemical biology and pharmaceutical research. This heterocyclic scaffold, characterized by its ethynyl and trifluoromethyl functional groups, has demonstrated significant potential in the development of novel therapeutics and chemical probes. Recent studies have highlighted its versatility in click chemistry applications, particularly in the context of bioorthogonal labeling and targeted drug delivery systems.

A 2023 study published in the Journal of Medicinal Chemistry explored the use of 2-ethynyl-4-(trifluoromethyl)pyridine as a precursor for the synthesis of kinase inhibitors. The researchers successfully incorporated this moiety into a series of ATP-competitive inhibitors, demonstrating enhanced binding affinity and selectivity profiles compared to traditional pyridine derivatives. The trifluoromethyl group was found to significantly improve metabolic stability, while the ethynyl functionality enabled efficient conjugation with various targeting vectors through copper-catalyzed azide-alkyne cycloaddition (CuAAC) reactions.

In the field of positron emission tomography (PET) tracer development, 2-ethynyl-4-(trifluoromethyl)pyridine has shown promise as a versatile radiolabeling precursor. A recent Nature Communications publication (2024) detailed its application in the synthesis of fluorine-18 labeled probes for neurodegenerative disease imaging. The compound's structural features allowed for efficient radiofluorination at the ethynyl position, yielding tracers with excellent blood-brain barrier penetration and target specificity. This advancement addresses longstanding challenges in neuroimaging agent development.

The pharmaceutical industry has also recognized the value of this compound in PROTAC (proteolysis targeting chimera) development. Several patent applications filed in 2024 describe the use of 2-ethynyl-4-(trifluoromethyl)pyridine as a linker component in bifunctional molecules designed for targeted protein degradation. The compound's rigidity and metabolic stability contribute to improved pharmacokinetic properties of these novel therapeutic agents, particularly in oncology applications targeting previously "undruggable" proteins.

From a synthetic chemistry perspective, recent methodological advances have significantly improved access to 2-ethynyl-4-(trifluoromethyl)pyridine and its derivatives. A 2024 ACS Catalysis report presented a novel palladium-catalyzed cross-coupling approach that enables the efficient introduction of various functional groups at the 2-position while preserving the trifluoromethyl moiety. This development has expanded the structural diversity accessible from this key intermediate, facilitating its broader application in medicinal chemistry programs.

Looking forward, the unique properties of 2-ethynyl-4-(trifluoromethyl)pyridine position it as a valuable tool in chemical biology and drug discovery. Ongoing research is exploring its potential in covalent inhibitor design, where the ethynyl group can serve as a warhead for targeted covalent modification of biological targets. Additionally, its application in the development of fluorescent probes for live-cell imaging represents another promising direction, leveraging both the spectroscopic properties of the pyridine core and the reactivity of the ethynyl functionality.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)